Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lipustobart
- Development stage
- Phase 1
- Lead developer
- Livzon Monoclonal Antibody
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Lipustobart (LZM009) is a human IgG4 monoclonal antibody that binds to PD-1 molecules on the surface of T-cells, blocks the PD-1/PD-Ligand 1 (PD-L1) pathway, and reactivates T cells to kill cancer cells. It was developed by Livzon Pharmaceutical Group through its subsidiary Livzon Mabpharm. The drug has completed clinical dose exploration trials in both China and the United States and has undergone extensive clinical trials, including pivotal trials in thymic cancer in China, with promising initial safety and efficacy data.
- Other names
- lipustobart利普苏拜单抗
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on lipustobart.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lipustobart.